Abstracts tagged "Systemic sclerosis"

Abstract Number: 0913 • ACR Convergence 2020
Systemic Sclerosis Portends a Higher Risk of Conduction and Rhythm Disorders at Diagnosis and During Disease Course: Results from a US Population Based Study
Yasser Radwan¹, Reto Kurmann², Avneek Singh Sandhu³, Edward El-Am⁴, Cynthia Crowson², Eric Matteson⁵, Thomas Osborn², Kenneth Warrington⁶, Rekha Mankad² and Ashima Makol², ¹Mayo Clinic, Rochester, Minnesota, USA, Lansing, MI, ²Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ³Mayo Clinic, Rochester, Minnesota, USA, Dayton, OH, ⁴Indiana University School of Medicine, Indianapolis, IN, ⁵Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, MN, ⁶Mayo Clinic, Rochester, MN
Background/Purpose: Cardiac involvement, including electrocardiogram (ECG) abnormalities, is associated with worse prognosis in systemic sclerosis (SSc). We studied the incidence, risk factors and outcomes of…
Abstract Number: 1379 • ACR Convergence 2020
Clinical Outcomes Among Participants with Diffuse Systemic Sclerosis Contracting COVID-19 During Clinical Studies of Lenabasum: A Case Series
Robyn Domsic¹, Lorinda Chung², Jerry Molitor³, Robert Spiera⁴, Bradley Bloom⁵, Barbara White⁶ and Quinn Dinh⁶, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, ³University of Minnesota, Minneapolis, MN, ⁴Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA, New York, NY, ⁵Corbus Pharmaceuticals Inc, Norwood, MA, ⁶Corbus Pharmaceuticals, Norwood, MA
Background/Purpose: Patients with systemic sclerosis (SSc) may be at increased risk for severe outcomes with COVID-19, given the high rate of immunosuppressive medication use, underlying…
Abstract Number: 1909 • ACR Convergence 2020
High-density Proteomic Analysis of Skin Blister Fluid and Plasma in Systemic Sclerosis Identifies Local and Systemic Differences for Key Proteins
Kristina Clark¹, Corrado Campochiaro², Eszter Csomor³, Adam Taylor³, Katherine Nevin³, Mary Morse³, Voon Ong⁴, Emma Derrett-Smith⁵, Nicolas Wisniacki³, Shaun Flint³ and Christopher Denton¹, ¹University College London, London, United Kingdom, ²Royal Free Hospital NHS trust, London, United Kingdom, ³GlaxoSmithKline, Stevenage, United Kingdom, ⁴UCL, London, United Kingdom, ⁵University College London Division of Medicine, London, United Kingdom
Background/Purpose: Simultaneous analysis of multiple proteins in biological fluids offers insight into the pathogenesis of SSc. Here, we report a proteomic analysis of plasma and…
Abstract Number: 0914 • ACR Convergence 2020
Serious Infections in People with Systemic Sclerosis: A National U.S. Study
Jasvinder Singh¹ and John Cleveland¹, ¹University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To study incidence, time-trends and outcomes of serious infections in systemic sclerosis (SSc).Methods: We used the 1998-2016 U.S. National Inpatient Sample data. We examined…
Abstract Number: 1380 • ACR Convergence 2020
Digital Occlusive Arterial Disease on Laser Doppler Flowmetry Increases the Risk of Digital Ischemic Complications in Systemic Sclerosis: Results from a Single Center Referral Cohort (2001-2018)
Yasser Radwan¹, Tina Gunderson², Cynthia Crowson², David Liedl², Kenneth Warrington³, Paul Wennberg² and Ashima Makol², ¹Mayo Clinic, Rochester, Minnesota, USA, Lansing, MI, ²Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ³Mayo Clinic, Rochester, MN
Background/Purpose: Vascular dysfunction is a key feature of systemic sclerosis (SSc), manifesting clinically as Raynaud’s phenomenon (RP) with or without digital ischemia. Laser doppler flowmetry…
Abstract Number: 1910 • ACR Convergence 2020
Integrated Molecular Analysis of Systemic Sclerosis Skin and Blood Highlights Significant Differences Between Major Autoantibody Subgroups
Kristina Clark¹, Corrado Campochiaro², Eszter Csomor³, Adam Taylor³, Katherine Nevin³, Nicholas Galwey³, Mary Morse³, Voon Ong⁴, Emma Derrett-Smith⁵, Shaun Flint³ and Christopher Denton¹, ¹University College London, London, United Kingdom, ²Royal Free Hospital NHS trust, London, United Kingdom, ³GlaxoSmithKline, Stevenage, United Kingdom, ⁴UCL, London, United Kingdom, ⁵University College London Division of Medicine, London, United Kingdom
Background/Purpose: The major antinuclear autoantibodies of systemic sclerosis (SSc) associate with different skin score trajectories and risk of internal organ manifestations. To elucidate molecular differences…
Abstract Number: 0916 • ACR Convergence 2020
Validating Autoantibody Associations and Clinical Impact of Severe Gastrointestinal Involvement in Systemic Sclerosis
Fiza Ahmed¹, Svetlana Nihtyanova¹, Stamatia Chatzinikolaou², Voon Ong¹, Charles Murray² and Christopher Denton³, ¹Centre for Rheumatology, Royal Free Campus, UCL Division of Medicine, UK, London, United Kingdom, ²Department of Gastroenterology, Royal Free London Foundation Trust, UK, London, United Kingdom, ³University College London, London, United Kingdom
Background/Purpose: Patients with systemic sclerosis (SSc) frequently experience gastrointestinal (GI) symptoms, ranging from mild to debilitating in severity. Better prediction of those most at risk…
Abstract Number: 1381 • ACR Convergence 2020
Real-World Mono-, Double and Triple Combination Treatment Patterns with Macitentan in Patients with Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (PAH-CTD): Evidence from the Combined OPUS/OrPHeUS Dataset
Matthew Lammi¹, Kelly Chin², Nick H. Kim³, Vallerie McLaughlin⁴, Roham Zamanian⁵, Megan Flynn⁶, Sandrine Leroy⁷, Rose Ong⁷, Graham Wetherill⁷ and Richard Channick⁸, ¹Lousiana State University Health Sciences Center, New Orleans, LA, ²UT Southwestern Medical Center, Dallas, TX, ³University of California San Diego, La Jolla, CA, ⁴University of Michigan, Ann Arbor, MI, ⁵Stanford University School of Medicine, Stanford, CA, ⁶Actelion Pharmaceuticals US, Inc., South San Francisco, CA, ⁷Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, ⁸University of California Los Angeles, Los Angeles
Background/Purpose: Patients with PAH-CTD have a worse prognosis than patients with most other PAH etiologies. The OPsumit® USers (OPUS) Registry and OPsumit® Historical USers (OrPHeUS)…
Abstract Number: 1911 • ACR Convergence 2020
IL-11 Expression in Systemic Sclerosis Pulmonary Fibroblasts Is Mediated by Caspase-1
Caya McFalls¹ and Carol Artlett¹, ¹Drexel University College of Medicine, Philadelphia
Background/Purpose: Interleukin-11 (IL-11) has been shown to be associated with idiopathic pulmonary fibrosis, cardiac and kidney fibrosis. However, conflicting data shows IL-11 can be either…
Abstract Number: 0917 • ACR Convergence 2020
Drug-Drug Interaction Study of Nintedanib (Ofev®) and the Combination of Ethinylestradiol and Levonorgestrel (Microgynon®) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Madelon Vonk¹, Mandy Avis², Kristell Marzin³, Salome Mack³, Sven Wind³ and Martina Gahlemann⁴, ¹Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Netherlands, ²Boehringer Ingelheim B.V., Alkmaar, The Netherlands, Alkmaar, Netherlands, ³Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, Biberach an der Riss, Germany, ⁴Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland
Background/Purpose: Nintedanib is a tyrosine kinase inhibitor that has been approved for the treatment of SSc-ILD. As nintedanib may cause fetal harm, patients taking nintedanib…
Abstract Number: 1382 • ACR Convergence 2020
Changes in Imaging Markers in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Treated with Nintedanib: Sub-Study of the SENSCIS Trial
Stephen Humphries¹, Eric Hachulla², Mark Hamblin³, Takashi Ogura⁴, Dag Wormanns⁵, Carina Ittrich⁶, Frank Risse⁶, Margarida Alves⁷, Martina Gahlemann⁸ and David Lynch⁹, ¹National Jewish Health, Denver, Colorado, USA, Denver, CO, ²Department of Internal Medicine and Clinical Immunology, Université de Lille, Lille, France, Lille, France, ³University of Kansas Hospital, Kansas City, Kansas, USA, Kansas City, KS, ⁴Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Centre, Yokohama, Japan, Yokohama, Japan, ⁵Evangelische Lungenklinik, Berlin, Germany, Berlin, Germany, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, Biberach an der Riss, Germany, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁸Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ⁹National Jewish Health, Denver, Colorado, USA, Denver
Background/Purpose: In the SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) (mL/year) over 52 weeks by…
Abstract Number: 1912 • ACR Convergence 2020
Novel Role of Thy-1 (CD90) in the Pathogenesis of Skin Fibrosis
Roberta Goncalves Marangoni¹, Stacey Duemmel², Marc Nuzzo², Ananta Paine¹, Christopher Ritchlin³ and Benjamin Korman³, ¹University of Rochester Medical Center, Rochester, NY, ²Department of Medicine, University of Rochester Medical Center, Rochester, ³Department of Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Thy-1 (CD90) is a GPI-anchored cell surface protein that is highly expressed in subsets of fibroblasts. Previous work has shown that Thy-1 deficiency exacerbates…
Abstract Number: 0382 • ACR Convergence 2020
Increased Rates of Obstetric Complications Prior to Systemic Sclerosis Diagnosis
Melody Chung¹, Kathleen Kolstad², Makdine Dontsi³, Poonam Manwani⁴, Hongyu Zhao⁵, Debbie Postlethwaite³, Sumana Kesh⁶, Julia Simard⁷ and Lorinda Chung⁸, ¹Stanford University, Stanford, CA, ²Division of Immunology & Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ³Division of Research, Kaiser Permanente Northern California, Oakland, CA, ⁴UCLA-Olive View Rheumatology Fellowship, Los Angeles, CA, ⁵Department of Internal Medicine, Kaiser Permanente Santa Clara, Santa Clara, CA, ⁶Kaiser Permanente Santa Clara, Santa Clara, CA, ⁷Stanford Medicine, Stanford, CA, ⁸Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA
Background/Purpose: Vasculopathy and immune dysfunction likely precede the diagnosis of systemic sclerosis (SSc) by years as evidenced by longstanding Raynaud’s phenomenon prior to diagnosis. Poor…
Abstract Number: 0918 • ACR Convergence 2020
Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) with and Without Gastroesophageal Reflux Disease: Further Analyses of the SENSCIS Trial
Kristin Highland¹, Gerard Criner², Petros Sfikakis³, Hilario Nunes⁴, Wendy Stevens⁵, Corinna Miede⁶, Margarida Alves⁷ and Michael Kreuter⁸, ¹Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ²Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, ³National Kapodistrian University of Athens Medical School, Athens, Greece, ⁴Department of Pulmonology, Hôpital Avicenne, APHP, Bobigny, France, Bobigny, France, ⁵Department of Rheumatology, St Vincent's Hospital, Melbourne, Victoria, Australia, Fitzroy, Victoria, Australia, ⁶mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach (Taunus), Germany, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁸Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Care Medicine, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany, Heidelberg, Germany
Background/Purpose: Gastroesophageal reflux disease (GERD) is a common comorbidity in patients with SSc-ILD and may be associated with progression of SSc-ILD. In the SENSCIS trial…
Abstract Number: 1383 • ACR Convergence 2020
Tocilizumab Shows Potential in Preserving Lung Function in Systemic Sclerosis with Positive anti-topoisomerase-1 (Scl-70): A Single Centre Cohort Study
Yasir Suleman¹, Kristina Clark², Svetlana Nihtyanova³, Voon Ong⁴ and Christopher Denton², ¹Royal Free Hospital London NHS Trust, London, United Kingdom, ²University College London, London, United Kingdom, ³Centre for Rheumatology, Royal Free Campus, UCL Division of Medicine, UK, London, United Kingdom, ⁴UCL, London, United Kingdom
Background/Purpose: Recent Phase II (faSScinate) and Phase III (focuSSced) clinical trials of tocilizumab versus placebo in early dcSSc highlighted the potential impact of tocilizumab on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].